The Challenge
Planning to continue vaccine therapy without updated biomarker testing.
Our Impact
We advocated for biomarker retesting at recurrence, explaining how genomic biomarkers can change over time and affect treatment options.
The Outcome
Retesting revealed a change in biomarker status, strengthening the rationale for combining vaccine therapy with chemotherapy and enabling a more comprehensive treatment plan.
